Details for Patent: 11,123,299

Which drugs does patent 11,123,299 protect, and when does it expire?

Patent 11,123,299 protects DROSPIRENONE and SLYND and is included in two NDAs.

This patent has sixty-nine patent family members in thirty-one countries.

Summary for Patent: 11,123,299

Title:	Synthetic progestogens and pharmaceutical compositions comprising the same
Abstract:	Described herein are synthetic progestogens, such as 6β,7β:15β,16β-Dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
Inventor(s):	Philippe Perrin, Jose Luis Velada, Dominique Drouin
Assignee:	Laboratorios Leon Farma SA
Application Number:	US17/216,419
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,123,299
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 11,123,299

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Exeltis Usa Inc	DROSPIRENONE	drospirenone	TABLET, CHEWABLE;ORAL	216285-001	Jun 29, 2022		DISCN	Yes	No			Y
Exeltis Usa Inc	SLYND	drospirenone	TABLET;ORAL	211367-001	May 23, 2019		RX	Yes	Yes			Y

International Family Members for US Patent 11,123,299

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2588114		CA 2020 00023	Denmark
European Patent Office	2588114		2020C/518	Belgium
European Patent Office	2588114		19/2020	Austria
European Patent Office	2588114		C202030026	Spain
European Patent Office	2588114		301123	Netherlands
European Patent Office	2588114		PA2021523	Lithuania
European Patent Office	2588114		LUC00227	Luxembourg